Dan Passeri
Chief Executive Officer
Replay available
Cue Biopharma, Inc. (CUE) Q1 2025 Earnings Call
Cue Biopharma, Inc. (NASDAQ: CUE) Q1 2025 earnings conference call, held 2025-05-15. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Matteo Levassetti
Chief Medical Officer
Dr. Richard DiPaolo
Professor and Chair, Department of Molecular Microbiology and Immunology at St. Louis University
Dr. Andy Cope
Professor and Head, Center for Rheumatic Diseases at King's College London
Steve Quayle
Senior Vice President of Research and Translational Medicine
Sam Rodriguez
Analyst at JMP Citizens Bank
Amin Makaram
Analyst at Jefferies
Leland Gershall
Analyst at Oppenheimer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Cue Biopharma, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.696 Good morning and welcome to the QBioPharma's novel biologics portfolio. 00:00:04.696 -- 00:00:07.880 At this time, all attendees are in a listen-only mode. 00:00:07.880 -- 00:00:12.625 Today's call will focus on a review of Q's novel biologics development platform for immobilizing 00:00:12.625 -- 00:00:17.570 the immune system. Joining me on today's call is QBioPharma's chief executive officer, 00:00:17.570 -- 00:00:20.914 Dan Passari, two recognized T-cell researchers, Dr. 00:00:20.914 -- 00:00:24.938 Richard DiPaolo and Dr. Andy Cope, and members of Q Management. 00:00:24.938 -- 00:00:29.045 Please note that this presentation and discussion is being recorded and will be available 00:00:29.045 -- 00:00:34.234 in the Investors and Media section of the company's website at qbiopharma.com 00:00:34.234 -- 00:00:38.742 for the next 30 days. Additionally, some of the statements we make on this call will 00:00:38.742 -- 00:00:42.568 include forward-looking statements within the meaning of the Private Securities Litigation 00:00:42.568 -- 00:00:47.576 Reform Act of 1995. Actual results could differ materially from those stated or 00:00:47.576 -- 00:00:51.842 implied by these forward-looking statements due to important risks and uncertainties 00:00:51.842 -- 00:00:56.108 associated with the company's business, including those set forth in the risk factors 00:00:56.108 -- 00:01:00.555 and in management's discussion and analysis of financial condition and results of operations 00:01:00.555 -- 00:01:05.601 section of QBioPharma's Annual report on Form 10-K for the year ended December 00:01:05.601 -- 00:01:10.607 31, 2024, filed on March 31, 2025. It's quarterly 00:01:10.607 -- 00:01:14.852 report on Form 10-Q filed on May 12, 2025, 00:01:14.8...